Oncoimmunology: A Practical Guide for Cancer Immunotherapy

Front Matter ....Pages i-x
 Principles of Oncoimmunology  (Laurence Zitvogel, Guido Kroemer)....Pages 1-2
Front Matter ....Pages 3-3
 The Human Tumor Microenvironment  (Yann Vano, Nicolas A. Giraldo, Wolf Herman Fridman, Catherine Sautès-Fridman)....Pages 5-21
 CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy  (Weimin Wang, Michael Green, J. Rebecca Liu, Theodore S. Lawrence, Weiping Zou)....Pages 23-39
 Mutant Epitopes in Cancer  (Martin Rao, Liu Zhenjiang, Qingda Meng, Georges Sinclair, Ernest Dodoo, Markus Maeurer)....Pages 41-67
 The Secrets of T Cell Polarization  (Thaiz Rivera Vargas, Lionel Apetoh)....Pages 69-95
 Regulatory T Cells: Their Role, Mechanism of Action, and Impact on Cancer  (Anthony R. Cillo, Dario A. A. Vignali)....Pages 97-113
 Purinergic Receptors: Novel Targets for Cancer Immunotherapy  (Dipti Vijayan, Mark J. Smyth, Michele W. L. Teng)....Pages 115-141
 Plasmacytoid DC/Regulatory T Cell Interactions at the Center of an Immunosuppressive Network in Breast and Ovarian Tumors  (N. Bendriss-Vermare, N. Gourdin, N. Vey, J. Faget, V. Sisirak, I. Labidi-Galy et al.)....Pages 143-161
 Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells  (Camille Guillerey, Mark J. Smyth)....Pages 163-180
 Biology of Myeloid-Derived Suppressor Cells  (Kevin Alicea-Torres, Dmitry I. Gabrilovich)....Pages 181-197
 Effect of Pharmaceutical Compounds on Myeloid-Derived Suppressor Cells  (Mélanie Bruchard, Francois Ghiringhelli)....Pages 199-213
 Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance  (Oliver Kepp, Jonathan Pol, Laurence Zitvogel, Guido Kroemer)....Pages 215-229
 Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies  (Anna S. Berghoff, Jakob Nikolas Kather, Dirk Jäger)....Pages 231-246
Front Matter ....Pages 247-247
 Peptide-Based Therapeutic Cancer Vaccines  (Cornelis J. M. Melief)....Pages 249-261
 Cancer Vaccines for HPV Malignancies  (Maria Agarwal, Cornelia Trimble)....Pages 263-274
 NK Cell-Based Therapies  (Laura Chiossone, Eric Vivier)....Pages 275-288
 IDO/TDO Inhibition in Cancer  (George C. Prendergast, William J. Malachowski, Arpita Mondal, Peggy Scherle, Alexander J. Muller)....Pages 289-307
Front Matter ....Pages 309-309
 Tumor-Targeted Antibodies  (Aurélien Marabelle)....Pages 311-319
 PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies  (Annette Paschen, Dirk Schadendorf)....Pages 321-331
 Immune Checkpoint Inhibition in Lung Cancer  (Daniel Morgensztern, Roy S. Herbst)....Pages 333-344
 PD-1 Blockade in Renal Cell Carcinoma  (Lisa Derosa, Bernard Escudier)....Pages 345-355
 BCG and Anti-PDL-1 Ab in Bladder Cancers  (Pernelle Lavaud, Yohann Loriot)....Pages 357-369
 PD-L1 and Other Immunological Diagnosis Tools  (Nicolas A. Giraldo, Janis M. Taube)....Pages 371-385
 Oncolytic Viruses: T-VEC and Others  (Rutika Mehta, Igor Puzanov)....Pages 387-403
Front Matter ....Pages 405-405
 Innate Immune Receptors in the Regulation of Tumor Immunity  (Sho Hangai, Yoshitaka Kimura, Tadatsugu Taniguchi, Hideyuki Yanai)....Pages 407-427
 Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer  (Ignacio Melero, Elisabeth Pérez-Ruiz, Alfonso R. Sanchez-Paulete, Alvaro Teijeira, Angela Aznar, Miguel F. Sanmamed)....Pages 429-446
 The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer  (Mélodie Bonvalet, Romain Daillère, Maria P. Roberti, Conrad Rauber, Laurence Zitvogel)....Pages 447-462
 Local Immunotherapies of Cancer  (Thomas U. Marron, Linda Hammerich, Joshua Brody)....Pages 463-481
 Strategies to Reduce Intratumoral Regulatory T Cells  (C. Maherzi, F. Onodi, E. Tartour, M. Terme, C. Tanchot)....Pages 483-506
 Synergy Between Radiotherapy and Immunotherapy  (Sandra Demaria, Sophia Bornstein, Silvia C. Formenti)....Pages 507-524
 Predictors of Response to Immune Checkpoint Blockade  (Miles C. Andrews, Jennifer A. Wargo)....Pages 525-544
Front Matter ....Pages 545-545
 Immune Therapies in Phase 1 Trials  (Sophie Postel-Vinay, Jean-Charles Soria)....Pages 547-563
 Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors  (Lucia Festino, Paolo A. Ascierto)....Pages 565-578
 Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting  (Alexander M. M. Eggermont, Caroline Robert)....Pages 579-591
 Immunotherapy for Prostate Cancer: An Evolving Landscape  (Wendy Mao, Charles G. Drake)....Pages 593-606
 Challenges of Oncoimmunology for Ovarian and Breast Cancers  (Mathilde Saint-Ghislain, Marie Bretagne, Marie-Paule Sablin, Emanuela Romano)....Pages 607-619
 Challenges in Colorectal Cancer: From Vaccines to Macrophage Repolarization  (Niels Halama)....Pages 621-639
 Current Status of Immuno-Oncology in Hematologic Cancers  (Bertrand Routy, David Ghez)....Pages 641-655
 Immunotherapy of Gliomas  (Michael Platten)....Pages 657-664
 Assessing T Cell Receptor Affinity and Avidity Against Tumor Antigens  (Mathilde Allard, Michael Hebeisen, Nathalie Rufer)....Pages 665-679
 Immune Monitoring of Blood and Tumor Microenvironment  (Petra Baumgaertner, Kalliopi Ioannidou, Daniel E. Speiser)....Pages 681-694
 Toward Engineered Cells as Transformational and Broadly Available Medicines for the Treatment of Cancer  (Cedrik M. Britten, Laura A. Johnson, Alfonso Quintás-Cardama, Neil C. Sheppard, Axel Hoos)....Pages 695-717
Front Matter ....Pages 719-719
 Concluding Remarks  (Pedro Romero, Wolf H. Fridman)....Pages 721-724